Skip to main content

icnlive

Menu
Menu
icn.lıve
WATCH LIVE. THINK BUSINESS.
Menu
X-twitter Linkedin-in Instagram Youtube

© 2026 ICN.LIVE

ICN.live

Adnan Al-Jaziri

  • 4 min read

Make us preferred on Google

  • 4 min read

PUBLISHED BY ICN PRESS

  • Researchers at Karolinska Institutet and KTH developed a more effective way to produce insulin-generating cells from human stem cells.
  • The new cells showed a strong glucose response in lab tests and reversed diabetes in mice after transplantation.
  • This advance brings regenerative medicine closer to a real type 1 diabetes treatment option for patients.
  • Scientists performed the transplantation through the eye, offering a less invasive path for future procedures.

Improved method for creating insulin-producing cells now gives scientists a better tool against type 1 diabetes treatment failures. Researchers at Karolinska Institutet and KTH Royal Institute of Technology shared their results in Stem Cell Reports. Their work focuses on a new process for growing cells from human stem cells. These cells helped control blood sugar regulation in both lab tests and live animals.

Type 1 diabetes happens when the immune system attacks and kills pancreatic beta cells in the body. Once those cells are gone, the body cannot pull glucose from the blood on its own. Patients need insulin shots every day because their bodies stop making enough insulin to survive. Scientists have tried for years to grow new cells in a lab to replace the ones the body loses. Past efforts gave mixed results because the cells were not mature or pure enough to work well.

The new process fixes those problems by giving cells more time and better conditions to grow fully. Scientists now produce cells that are cleaner and more complete than those made by older methods. In lab tests, the cells sensed glucose and pushed out insulin at levels doctors would find useful. As I see it, the jump in cell quality is what makes this study stand out from past research.

Researchers Prove Results in Living Animals

The team put these new cells into mice that had diabetes to see how they worked in a live body. Those mice slowly got back the ability to manage their own blood sugar regulation after the transplant. Scientists placed the cells in the front part of the eye so they could watch them without deep surgery. That spot lets researchers see the cells clearly and check their progress without cutting into organs. It also lowers the risk for the animal and makes the whole process easier to track over time.

The mice getting better is strong early proof that the cells work the way scientists hoped they would. Improved method for creating insulin-producing cells like these could one day cut the need for daily insulin shots. The mice did not reject the cells right away, which shows good early signs of the body accepting them. These results give researchers a solid reason to think about testing the cells in humans one day.

Regenerative Medicine Gets a Real Push Forward

The field of regenerative medicine needs a way to grow large amounts of good cells before it can help patients. Old methods made too many weak or unfinished cells, which hurt the overall results in tests. This new process makes more useful cells per batch than any older method published so far. More good cells in each batch means better and steadier results when scientists move to the next step.

For people dealing with type 1 diabetes treatment every single day, this news gives real hope for change. Pancreatic beta cells that the immune system kills do not come back on their own with any current drug. A steady supply of lab-grown cells that work like real ones could change how doctors treat this disease. Improved method for creating insulin-producing cells could also help researchers working on other forms of diabetes. Scientists will keep working on the process before they try it on human patients.

The Path Toward Insulin Independence

Many researchers in this field want to help patients reach full insulin independence without daily injections. To get there, the new cells need to last a long time, read glucose levels well, and avoid immune attacks. This study shows the cells can do the first two things better than any past work has shown. The immune system question is still open and needs more work before doctors can use this in people.

An improved method for creating insulin-producing cells is a real move forward in solving that problem step by step. Karolinska Institutet and KTH have created a base that other science teams around the world can now use. For the many millions of people who manage type 1 diabetes each day, this kind of news matters a lot. Pancreatic beta cells grown in a lab now act more like real body cells than they ever did before. What comes next will show how fast this work can turn into real help for real patients.

TAGS
  • Health

EXPLORE MORE ON:

TechAICapitalPoliticsBanking
how to build discipline
  • Entrepreneur

How founders build discipline depends on system design, not personal willpower. Many people frame discipline as a fixed trait. They believe a person either has it or does not. The evidence points elsewhere. Discipline usually reflects the environment around a choice. It rarely reflects the character of the person making it. For a founder, that gap matters. A company runs on thousands of small choices made under pressure. The design of a day, a calendar, and a workspace shapes what a founder does next. Small structural choices carry more weight than raw effort.

How Founders Build Discipline Without Relying On Motivation

Willpower is a limited resource. It drains as the day goes on. Strong morning plans often fall apart by evening. A founder who runs on motivation loses focus once fatigue sets in. Structure works another way. A system holds a decision in place no matter the mood or the hour. This idea sits at the core of disciplined entrepreneurship. A repeatable process replaces the daily argument with oneself. The founders who last are not more motivated than their peers. They have removed the moments where motivation gets tested. Motivation feels reliable in the moment. It is not. A plan written on a calm morning survives a hard afternoon far better than a promise made under stress.

Cutting The Decision Fatigue Founders Face Every Day

Decision fatigue means the drop in judgment after many choices. The decision fatigue founders face builds fast. Each open question pulls attention from the next. One fix is to decide ahead of time. A founder maps annual goals once. Then a weekly review sets the priorities. This turns hundreds of daily debates into plain execution. Strong founder productivity habits often come down to this one move. Deciding early guards the energy a leader needs for real work. The daily habits of successful founders show fewer open choices, not more effort.

Replace Weak Habits, Do Not Ban Them

Business discipline also depends on how a founder treats weak habits. Force rarely works for long. A better method swaps the weak habit for a workable one. Then the founder improves that swap over time. Say a leader checks metrics every hour under stress. One scheduled review can take the place of that pattern. Small, staged trades outlast sudden bans. The goal is not instant perfection. It is steady movement toward a better default. Each swap should feel easy to repeat. If it feels hard to sustain, it will not hold. Founders build lasting change through small wins, not through pressure.

The Case For Boring Systems

Good systems rarely feel thrilling. That is the point. A routine full of novelty is not truly a routine. Some founders chase new tools, methods, and frameworks. They mistake motion for progress. Plain, steady execution compounds in a way flashier work cannot. This is where how founders build discipline shows from the outside. The work looks dull and repetitive. Under it sits a set of choices made once and followed without argument. Over months and years, that structure divides the founders who ship from the ones who stall. In the end, how founders build discipline is a question of design, repeated until it holds.

  • 3 min read
Oura IPO Arrives
  • Oura

The Oura IPO gives you a clear read on how fast the smart ring market has changed. Oura filed to go public on September 3. The Finnish company built its name on sleep and health tracking, and the numbers show the payoff. Revenue nearly doubled to $1.21 billion for the nine months ending June 30. Oura sold 3.6 million rings over the past year. It now counts around 5 million paid members. The filing follows the launch of the Oura Ring 5, the slimmest and lightest model the company has made.

Early estimates put the offering near $2.5 billion, with a planned listing on Nasdaq. That scale tells you something simple. A product once seen as niche now carries the weight of a public company. The Oura IPO puts that shift in plain numbers.

Why the Oura IPO matters to buyers

Here is what affects you. Competition tends to lower prices and speed up feature releases. More rivals usually means faster upgrades and better value for the ring on your hand. Oura led the smart ring market for years, but rivals are arriving from every direction, each with its own angle. French company Circular says its next ring will let you tap to pay. Chinese company RingConn released a ring this year with haptic vibrations, small buzzes you feel on your finger. That shift changes what a ring can do.

The money behind the challengers

Indian company Ultrahuman raised $70 million this week, with backing from Qualcomm’s venture arm. Ultrahuman wants to build a ring running software on the device itself. Over time, the company says that could power AI features and even games. As a smart ring maker, Ultrahuman is aiming well past sleep scores. Backing from a chip giant like Qualcomm shows the goal is serious.

The Ultrahuman Ring Pro shows the plan in hardware. Priced at $479, it starts shipping in the US in mid-September. It carries a redesigned heart-rate sensor built to read cleaner signals while you sleep. A new dual-core processor, a chip with two cores, handles more accurate data and more work on the device.

The Ring Pro also comes out of a legal fight. Ultrahuman’s US business stalled in October 2025 after the US International Trade Commission ruled for Oura in a patent dispute. The ruling blocked the company from importing new ring inventory. So Ultrahuman rebuilt the Ring Pro with a new form factor to work around Oura’s patent.

Payments, screens, and the race ahead

Circular plans its Ring 3 series for early next year, with a Pro model and a Slim option. Both rings include an NFC chip, the same tap-to-pay tech in your phone, for contactless payments. They also add on-finger vibrations for silent alarms, reminders, and health alerts.

The direction is easy to see. Smart rings were once sold on the idea of stepping away from a screen while keeping tabs on your health. For years, a ring felt lighter than a smartwatch, easy to forget on your finger. That quiet appeal could fade if rings keep adding screens and buttons. Now the race is about how many phone-like features fit inside a two-gram titanium band. Some rings already carry screens, like the Pebble Halo, sold in India for now. Others promise touchpads, like the Dreame Ring. The Oura IPO lands in the middle of this rush.

What Oura Ring alternatives offer now

Shopping for Oura Ring alternatives now means more real choice. Buyers hunting for the best smart rings in 2026 can weigh payments, vibrations, and on-device software against Oura’s tracking. The Oura IPO does not settle the contest. It raises the stakes for every smart ring maker trying to lead. For you, more competition tends to mean more features and better prices ahead.

  • 4 min read
OpenAI GPT-6 Astra
  • GPT-6 Astra

GPT-6 Astra is OpenAI’s new frontier model, and its arrival brings two questions to the center of the AI market: what these systems can do, and what they cost to run. OpenAI describes Astra as its most capable and most aligned model so far. Access opened first to a limited set of organizations, then widened to paid users across ChatGPT Plus, Pro, Business, and Enterprise. The GPT-6 Astra release date fell in early September, with a limited preview ahead of broader access.

Developers can reach the model through the OpenAI API, Microsoft Azure, and Amazon Bedrock. The company built Astra for long, multi-step work rather than short chat. That design shows in the strongest gains, which sit in GPT-6 Astra computer use. OpenAI says the model can fill out online forms, update customer records, organize a calendar, run research, and draft summaries inside a user’s email or document editor. The aim is a system that finishes tasks, not one that only answers questions.

Business Intelligence & News

  • OpenAI’s advertising revenue reached a $1 billion annualized run rate, the company said.
  • The ad business is about 200 days old and now runs in more than 40 countries.
  • Self-service buying is expanding to India, Europe, the Middle East, and North Africa.
  • The push comes as OpenAI prepares to go public and defends an $852 billion valuation.
  • AI & TOOLS

What the GPT-6 Astra benchmarks show

The GPT-6 Astra benchmarks published by the company are aggressive. OpenAI says the model saturates FrontierMath Tier 4 at close to 98 percent, reaches 99.9 percent on ARC-AGI-3, and scores 100 percent on ExploitBench. Both the math and reasoning tests were designed to stay ahead of AI systems, so results this high point to a real step up. One caveat matters here. The ARC-AGI-3 score used a general-purpose setup that preserved the model’s reasoning and managed long context, so it is not a clean match with every earlier figure.

Independent testing gives a more measured read. Artificial Analysis found Astra roughly level with its predecessor on overall intelligence, and behind Claude Fable 5.1 on general reasoning, while gaining on coding at lower cost.

On computer-use speed, OpenAI reports a higher score on the OSWorld 2.0 test in about 47 percent less time per task than the prior model, GPT-5.6 Sol. For firms weighing automation of desk work, time per task can weigh as much as raw accuracy.

Cost and cybersecurity set the real test

GPT-6 Astra pricing is where the tradeoff shows most clearly. Standard rates run at 10 dollars per million input tokens and 50 dollars per million output tokens, about 2.5 times the prior flagship’s 4 and 20 dollar rates. OpenAI notes that Astra often uses fewer tokens for similar work, which can offset part of the higher rate. Whether that holds depends on the task. The number worth tracking is cost per finished result, not the headline token price.

On safety, Astra is the first OpenAI model to reach the Critical level for cybersecurity under the company’s internal framework. OpenAI says the model can find unknown security flaws and build ways to exploit them across well-defended systems without a person guiding each step. To limit misuse, the company restricts the most advanced exploit abilities and adds production safeguards. It also flagged a weakness in how well its monitors can read the model’s reasoning under pressure, and named that as open work.

The wider shift is about where value moves. As frontier models take on full tasks rather than single answers, the market question moves from capability alone to capability set against cost and risk. The OpenAI GPT-6 Astra release, arriving alongside strong models from rival labs, brings that calculation into the open for enterprise buyers.

  • 4 min read

Share this post

on your favourite social platforms

or copy the link